Jefferies Pothena Corporation (PRTA) After negative test results

Jefferies Ptcena Corporation Plc on May 27 (NASDAQ:Prta) Purchase and price target reduced to $ 32 to $ 6.

The significant price reduced the company’s announcement.

Biofarmatia research laboratory with a group of scientists working on immunomodulation therapy.

A research that is in a research work in a research work that conducts analytical research, Phaena Corporation (PTAQ: PRTA) is not working for the second time of III III, so it is to reduce the OPEX related to Birtamimab. Although more updates are expected in June, the next investor focus, PRX-012 for Alzheimer’s in I / II I / II.

The PRX-012 phase is expected to spread data for I / II until August. However, they said they were cautious about the results because they could not show the necessary effectiveness.

Pothena Corporation (PTAQ: PRTA) is a clinical-stage neurological company that reveals and developing novel therapy for serious diseases. Includes both amyloidosis, alzheimer’s disease, amyloidosis, parkingist’s disease, amyloidosis, parkinson’s disease and other nevodegenerative diseases and other nevodegeable diseases and other nevodegeable diseases.

The TGT causes more than the fact that we adopt their potential as an investment, the giving higher income of some of our beliefs, and the fact that limited risks are limited. If you are looking for an AI stock with more promising and 100x upside potential than TGT, review our report on this Cheap EU reserves.

Read the next: 10 borrowed debt free of these Penny shares and 10 non-stop shares that can double your money.

Disclosure: No.